Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biodesix Inc (NQ: BDSX )

2.610 +0.020 (+0.77%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 12, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 50,989
Open 2.550
Bid (Size) 2.610 (29)
Ask (Size) 2.660 (9)
Prev. Close 2.590
Today's Range 2.500 - 2.660
52wk Range 1.250 - 10.22
Shares Outstanding 39,982,048
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Biodesix Named a Top 100 Healthcare Technology Company of 2022
From Biodesix, Inc.
Via Business Wire
Biodesix: Q2 Earnings Insights
  Biodesix (NASDAQ:BDSX) reported its Q2 earnings results on Thursday, August 4, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga

Performance

YTD
-55.08%
-55.08%
1 Month
+38.83%
+38.83%
3 Month
+55.36%
+55.36%
6 Month
-24.78%
-24.78%
1 Year
-64.97%
-64.97%

More News

Read More
Biodesix Announces Second Quarter 2022 Results and Highlights
From Biodesix, Inc.
Via Business Wire
Recap: Biodesix Q1 Earnings
Via Benzinga
Biodesix to Present at the Canaccord Genuity 42nd Annual Growth Conference
From Biodesix, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Biodesix to Present Data at IASLC 2022 World Conference Demonstrating that the VeriStrat® Test is Predictive of Progression Free Survival and Overall Survival in Patients with Low or Negative PD-L1 Treated with Immune Checkpoint Inhibitors
From Biodesix, Inc.
Via Business Wire
Biodesix to Report Second Quarter 2022 Financial Results on August 4, 2022
From Biodesix, Inc.
Via Business Wire
Akerna Shares Dip 53%, Here's 78 Biggest Movers From Yesterday
Via Benzinga
Looking Into Biodesix's Return On Capital Employed
Via Benzinga
Biodesix Obtains Medicare Coverage for the Nodify CDT® Lung Nodule Test
From Biodesix, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Biodesix Announces Research Agreement with Top US Cancer Center
From Biodesix, Inc.
Via Business Wire
Biodesix to Present at the 42nd Annual William Blair Growth Stock Conference
From Biodesix, Inc.
Via Business Wire
Biodesix to Present at the H.C. Wainwright Global Investment Conference
From Biodesix, Inc.
Via Business Wire
Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to be Presented at ATS 2022 International Conference
From Biodesix, Inc.
Via Business Wire
Biodesix Announces First Quarter 2022 Results and Highlights
From Biodesix, Inc.
Via Business Wire
66 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Biodesix to Report First Quarter 2022 Financial Results on May 11, 2022
From Biodesix, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2022
Via Benzinga
68 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
Via Benzinga
A Peek Into The Markets: US Stock Futures Down Ahead Of March Inflation Report
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.